SYDNEY, Australia and COLUMBIA, Miss., June 20 /PRNewswire/ -- Proteome Systems and the University of Missouri-Columbia -- have announced a collaboration to identify critical pathways involved in anti-cancer drug resistance and potential protein targets for therapeutic intervention using proteomics. Professor Stephen Alexander from the Division of Biological Sciences will lead the university team. His team has wide expertise in using a model organism to study how anti-cancer drugs work in cells.
Dr. Jenny Harry (VP Discovery Proteome Systems) said: ``We have chosen to collaborate with the University of Missouri-Columbia because they bring a new perspective to solving problems in the area of cancer. We are delighted to be working with a group of scientists who understand the value of proteomics to accelerate the discovery process. Under the collaboration, Proteome Systems will integrate this project into a larger in house cancer program.''
Dr. Stephen Alexander (Professor of Biological Sciences, University of Missouri-Columbia) said: ``We are excited to access the outstanding proteomics team at Proteome Systems along with their high throughput, integrated technology and bioinformatic platforms. We believe that the combination of skills and expertise between Proteome Systems and our group at the university provides a powerful approach to fast-track the identification of anti-cancer drug targets.''
Dr. Keith Williams (CEO Proteome Systems) said: ``Our discussions began with the cancer project but have already been extended. The agreement reached with the university includes Proteome Systems providing expert advice to the university and other researchers in the university on use of proteomics to drive research. We see good prospects for developing additional joint programs.''
Dr Jack Burns (Vice Provost for Research, University of Missouri) said: ``We want to be the best in applying the new field of proteomic technology to our research initiatives. We have identified proteomics and bioinformatics as key areas where the University is well placed to be leaders. We think the collaboration with Proteome Systems is an important step forward in achieving this goal.''
About Proteome Systems
Proteome Systems is a proteomics company with facilities in Sydney (50,000 sq. feet) and Boston (20,000 sq. feet). With our technology partners, we develop transforming technologies for high throughput proteomics which will be sold as a total solutions package (ProteomIQ(TM)). These technologies, integrated using a proprietary and sophisticated bioinformatics system, are implemented in our Discovery programs in the areas of infectious disease, cancer and aging.
About the University of Missouri-Columbia:
The University of Missouri-Columbia is the state of Missouri's flagship, land-grant campus and is a top research institution in the United States. In the past year, it had more than $100 million in research expenditures and is home to several nationally and internationally known scientists. The University of Missouri-Columbia is striving to become a national Comprehensive Cancer Center to continue the war on cancer. The special designation from the National Cancer Institute could bring the University special recognition for additional research money.
CONTACT: Dr. Keith Williams, Chief Executive Officer of Proteome Systems Ltd, 61-2-9889-1830, or keith.williams@proteomesystems.com; or Christian Basi, Assistant Director of University of Missouri-Columbia News Bureau, 573-882-4430, or BasiC@missouri.edu. |
